IP Library Granted Patent US 8,957,240
Granted Patent B2
US 8,957,240 · App. 13/953,236 · Granted Feb 17, 2015

Method for the purification of prostaglandins

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,957,240
App. No.
13/953,236
Granted
Feb 17, 2015
Kind
B2
Abstract

The present invention provides a method for the purification of a prostaglandin by supercritical fluid chromatography, said method comprising the use of a stationary phase and a mobile phase comprising carbon dioxide, provided that when the stationary phase is unmodified silica gel, the prostaglandin is not luprostiol. The invention also provides prostaglandins obtainable by the method.

Claims (39)

1. A method for the purification of a prostaglandin by supercritical fluid chromatography, said method comprising using a stationary phase and a mobile phase comprising carbon dioxide, wherein the stationary phase is diol and the prostaglandin is a compound of formula (I), a compound of formula (II), or a compound of formula (IV):

wherein,

V is C;

W is

X is CONR 12 R 13 or CO 2 R 12 ;

Y is

Z is C 1-20 -alkyl, C 2-20 -alkynyl, —O—(C 6-20 -aryl) or —(C 1-20 -alkyl)-(C 6-20 -aryl), wherein the aryl group is optionally substituted with one to three substituents selected from the group consisting of C 1-20 -alkyl, halo and C(halo) 3 ;

R 1 and R 2 are independently H or OH, or R 1 and R 2 together form

R 3 and R 4 are independently H or OH;

R 5 and R 6 are independently H or OH, or R 5 and R 6 together form

R 7 and R 8 are independently H, OH, halo or C 1-20 -alkyl; R 9 and R 10 are independently H or C 1-20 -alkyl, wherein the alkyl group is optionally substituted with one or more substituents selected from CONR 12 R 13 , CO 2 R 12 , and CO 2 − M + ; R 11 is C 1-20 -alkyl or —O—(C 1-20 -alkyl), wherein the alkyl group is optionally substituted with one or more substituents selected from CONR 12 R 13 , CO 2 R 12 , and CO 2 − M + ; R 12 and R 13 are independently selected from the group consisting of H and C 1-20 alkyl; M + is a counter cation; and

Halo is fluorine, chlorine, bromine or iodine.

2. A method according to claim 1 , wherein the prostaglandin is selected from the group consisting of:

3. A method according to claim 1 , wherein the prostaglandin is:

4. A method according to claim 1 , wherein the mobile phase further comprises at least one modifier.

5. A method according to claim 4 , wherein the at least one modifier is selected from the group consisting of at least one alcohol, acetonitrile, ethyl acetate, methylene chloride and a combination thereof.

6. A method according to claim 4 , wherein the at least one modifier includes an alcohol selected from the group consisting of methanol, ethanol, propanol, isopropanol and a combination thereof.

7. A method according to claim 4 , wherein the at least one modifier is present in a quantity from about 1% v/v to the carbon dioxide.

8. A method according to claim 4 , wherein the at least one modifier is present in a quantity from about 1% w/w to the carbon dioxide.

9. A method according to claim 4 , wherein the at least one modifier is present in a quantity from about 5% v/v to the carbon dioxide.

10. A method according to claim 4 , wherein the at least one modifier is present in a quantity from about 5% w/w to the carbon dioxide.

11. A method according to claim 1 , wherein the method provides a purified prostaglandin which is at least 99% chemically pure.

12. A method according to claim 1 , wherein the method provides a purified prostaglandin which is at least 99% isomerically pure.

13. A method for purifying a crude prostaglandin, comprising injecting the crude prostaglandin onto a column comprising a stationary phase, eluting the crude prostaglandin through the column using a mobile phase comprising supercritical carbon dioxide, and collecting a fraction comprising a purified prostaglandin, wherein the stationary phase is diol and the prostaglandin is a compound of formula (I), a compound of formula (II), or a compound of formula (IV):

wherein,

V is C;

W is

X is CONR 12 R 13 or CO 2 R 12 ;

Y is

Z is C 1-20 -alkyl, C 2-20 -alkynyl, —O—(C 6-20 -aryl) or —(C 1-20 -alkyl)-(C 6-20 -aryl), wherein the aryl group is optionally substituted with one to three substituents selected from the group consisting of C 1-20 -alkyl, halo and C(halo) 3 ;

R 1 and R 2 are independently H or OH, or R 1 and R 2 together form

R 3 and R 4 are independently H or OH;

R 5 and R 6 are independently H or OH, or R 5 and R 6 together form

R 7 and R 8 are independently H, OH, halo or C 1-20 -alkyl;

R 9 and R 10 are independently H or C 1-20 -alkyl, wherein the alkyl group is optionally substituted with one or more substituents selected from CONR 12 R 13 , CO 2 R 12 , and CO 2 − M + ;

R 11 is C 1-20 -alkyl or —O—(C 1-20 -alkyl), wherein the alkyl group is optionally substituted with one or more substituents selected from CONR 12 R 13 , CO 2 R 12 , and CO 2 − M + ;

R 12 and R 13 are independently selected from the group consisting of H and C 1-20 alkyl;

M + is a counter cation; and

Halo is fluorine, chlorine, bromine or iodine.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2022
From: JOHNSON MATTHEY PUBLIC LIMITED COMPANY
To: MACFARLAN SMITH LIMITED
Reel/Frame 061888/0166 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2016
From: HOGAN, ROBERT R.; ROSSI, RONALD
To: JOHNSON MATTHEY PUBLIC LIMITED COMPANY
Reel/Frame 037957/0497 →